1
|
Ben Ayed A, Akrout I, Staita K, Albert Q, Greff S, Simmler C, Ahrendt S, LaButti K, Lipzen A, He G, Savage E, Armengaud J, Kielbasa M, Navarro D, Drula E, Turbé-Doan A, Bertrand E, Lomascolo A, Chaduli D, Faulds CB, Chamkha M, Maalej A, Barry K, Grigoriev IV, Martin F, Zouari-Mechichi H, Sciara G, Mechichi T, Record E. Genome sequencing of Porostereum spadiceum to study the degradation of levofloxacin. ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY 2024; 270:115808. [PMID: 38198896 DOI: 10.1016/j.ecoenv.2023.115808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Revised: 12/05/2023] [Accepted: 12/08/2023] [Indexed: 01/12/2024]
Abstract
Despite various plans to rationalize antibiotic use, antibiotic resistance in environmental bacteria is increasing due to the accumulation of antibiotic residues in the environment. This study aimed to test the ability of basidiomycete fungal strains to biotransform the antibiotic levofloxacin, a widely-used third-generation broad-spectrum fluoroquinolone, and to propose enzyme targets potentially involved in this biotransformation. The biotransformation process was performed using fungal strains. Levofloxacin biotransformation reached 100% after 9 days of culture with Porostereum spadiceum BS34. Using genomics and proteomics analyses coupled with activity tests, we showed that P. spadiceum produces several heme-peroxidases together with H2O2-producing enzymes that could be involved in the antibiotic biotransformation process. Using UV and high-resolution mass spectrometry, we were able to detect five levofloxacin degradation products. Their putative identity based on their MS2 fragmentation patterns led to the conclusion that the piperazine moiety was the main target of oxidative modification of levofloxacin by P. spadiceum, leading to a decrease in antibiotic activity.
Collapse
Affiliation(s)
- Amal Ben Ayed
- Université de Sfax, Ecole Nationale d'Ingénieurs de Sfax, Laboratoire de Biochimie et de Génie enzymatique des lipases, 3038 Sfax, Tunisia; Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Imen Akrout
- Université de Sfax, Ecole Nationale d'Ingénieurs de Sfax, Laboratoire de Biochimie et de Génie enzymatique des lipases, 3038 Sfax, Tunisia; Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Karima Staita
- Université de Sfax, Ecole Nationale d'Ingénieurs de Sfax, Laboratoire de Biochimie et de Génie enzymatique des lipases, 3038 Sfax, Tunisia; Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Quentin Albert
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France; Aix-Marseille Université, INRAE, UMR1163, CIRM-CF, 13288 Marseille, France.
| | - Stéphane Greff
- Aix-Marseille Université, CNRS, IRD, Avignon Université, IMBE, UMR 7263, Station Marine d'Endoume, Rue de la Batterie des Lions, 13007 Marseille, France.
| | - Charlotte Simmler
- Aix-Marseille Université, CNRS, IRD, Avignon Université, IMBE, UMR 7263, Station Marine d'Endoume, Rue de la Batterie des Lions, 13007 Marseille, France.
| | - Steven Ahrendt
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Kurt LaButti
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Anna Lipzen
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Guifen He
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Emily Savage
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Jean Armengaud
- Université Paris-Saclay, Département Médicaments et Technologies pour la Santé, CEA, INRAE, SPI, 30200 Bagnols-sur-Cèze, France.
| | - Mélodie Kielbasa
- Université Paris-Saclay, Département Médicaments et Technologies pour la Santé, CEA, INRAE, SPI, 30200 Bagnols-sur-Cèze, France.
| | - David Navarro
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France; Aix-Marseille Université, INRAE, UMR1163, CIRM-CF, 13288 Marseille, France.
| | - Elodie Drula
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France; Architecture et Fonction des Macromolécules Biologiques, Centre National de la Recherche Scientifique, Aix-Marseille Université, 13288 Marseille, France; USC AFMB, Institut National de Recherche Agronomique, 13288 Marseille, France.
| | - Annick Turbé-Doan
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Emmanuel Bertrand
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Anne Lomascolo
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Delphine Chaduli
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France; Aix-Marseille Université, INRAE, UMR1163, CIRM-CF, 13288 Marseille, France.
| | - Craig B Faulds
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Mohamed Chamkha
- Université de Sfax, Centre de Biotechnologie de Sfax, Laboratoire des Bioprocédés Environnementaux, 3063 Sfax, Tunisia.
| | - Amina Maalej
- Université de Sfax, Centre de Biotechnologie de Sfax, Laboratoire des Bioprocédés Environnementaux, 3063 Sfax, Tunisia.
| | - Kerrie Barry
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
| | - Igor V Grigoriev
- US Department of Energy Joint Genome Institute, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; Department of Plant and Microbial Biology, University of California-Berkeley, Berkeley, CA 94720, USA.
| | - Francis Martin
- Université de Lorraine, INRAE, UMR1136, Interactions Arbres/Microorganismes, 54280 Champenoux, France.
| | - Héla Zouari-Mechichi
- Université de Sfax, Ecole Nationale d'Ingénieurs de Sfax, Laboratoire de Biochimie et de Génie enzymatique des lipases, 3038 Sfax, Tunisia.
| | - Giuliano Sciara
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| | - Tahar Mechichi
- Université de Sfax, Ecole Nationale d'Ingénieurs de Sfax, Laboratoire de Biochimie et de Génie enzymatique des lipases, 3038 Sfax, Tunisia.
| | - Eric Record
- Aix-Marseille Université, INRAE, UMR1163, Biodiversité et Biotechnologie Fongiques, 13288 Marseille, France.
| |
Collapse
|
2
|
Singh P, Walia V, Verma PK. Hypoglycemia and anxiolysis mediated by levofloxacin treatment in diabetic rats. J Diabetes Metab Disord 2023; 22:1197-1209. [PMID: 37975146 PMCID: PMC10638278 DOI: 10.1007/s40200-023-01234-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2022] [Accepted: 05/03/2023] [Indexed: 11/19/2023]
Abstract
Purpose The present study was designed to determine the effect of levofloxacin (LVX) treatment on the blood glucose level, insulin sensitivity, anxiety level, nitrite and MDA level of STZ induced diabetic rats. Methods Wistar rats were used in the present study. The rats were made diabetic by the administration of single dose of STZ (45 mg/kg, i.p.) and NAD (50 mg/kg, i.p.). The rats with the blood glucose level greater than 200 mg/dl were considered as diabetic (confirmed at day-3 of STZ-NAD administration). The non-diabetic rats were considered as control and received saline.Diabetic rats received metformin (50 mg/kg, p.o.) and LVX (20, 25, 30 and 35 mg/kg, i.p.) daily for 14 days (starting from the day at which STZ was injected). Following administration on 14th day,the blood sample was collected and the rats were subjected to behavioral assays for the determination of locomotor activity and anxiety level. Plasma was separated and used for the estimation ofnitrite and malondialdehyde (MDA)level. On 15th day OGTT was performed in the overnight fasted rats for the assessment of insulin sensitivity. Results The results obtained suggested that the administration of STZ-NAD induced the hyperglycemia at day-3 of administration. Diabetic rats displayed the significant increase in blood glucose, anxiety related behavior, MDA level while significant decrease in the insulin sensitivity and plasma nitrite level. Daily administration of metformin to the diabetic rats decreased the blood glucose level, increased the time spent at the center of open field, reversed the anxiety related behavior in LDT and EPM, did not affect the plasma nitrite level, decreased the plasma MDA level, decreased the fasting glucose level and AUC in OGTT assay. LVX (30 and 35 mg/kg) treatment significantly decreased the blood glucose level of diabetic rats. LVX (20, 25 and 30 mg/kg) treatment significantly decreased the number of square crossing while LVX (20, 25, 30 and 35) treatment significantly increased the time spent at the center of the field by the diabetic rats. LVX (20 and 35 mg/kg) treatment significantly reversed the STZ induced anxiety in LDT while LVX (20, 30 and 35 mg/kg) treatment significantly reversed the STZ induced anxiety in EPM test. LVX (20, 25 and 35 mg/kg) treatment significantly increased the plasma nitrite level and LVX (20-35 mg/kg) treatment significantly decreased the MDA level of diabetic rats. Further only LVX (35 mg/kg) treatment significantly decreased the fasting glucose level and increased the AUC of diabetic rats. Conclusion In conclusion, STZ-NAD administration increased the blood glucose level, anxiety related behavior, decreased the plasma nitrite and increased the MDA level. LVX administration potentiated the diabetogenic effects of STZ-NAD in rats. Daily administration of LVX decreased the blood glucose level of diabetic rats. LVX administration alleviated the STZ induced anxiety in OFT, LDT and EPM test. LVX administration increased the plasma nitrite level and decreased the lipid peroxidation in diabetic rats. Supplementary Information The online version contains supplementary material available at 10.1007/s40200-023-01234-0.
Collapse
Affiliation(s)
- Poonam Singh
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001 Haryana India
| | - Vaibhav Walia
- SGT College of Pharmacy, SGT University, Gurugram, Haryana India
| | - Prabhakar Kumar Verma
- Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001 Haryana India
| |
Collapse
|
3
|
Soraci L, Cherubini A, Paoletti L, Filippelli G, Luciani F, Laganà P, Gambuzza ME, Filicetti E, Corsonello A, Lattanzio F. Safety and Tolerability of Antimicrobial Agents in the Older Patient. Drugs Aging 2023; 40:499-526. [PMID: 36976501 PMCID: PMC10043546 DOI: 10.1007/s40266-023-01019-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/27/2023] [Indexed: 03/29/2023]
Abstract
Older patients are at high risk of infections, which often present atypically and are associated with high morbidity and mortality. Antimicrobial treatment in older individuals with infectious diseases represents a clinical challenge, causing an increasing burden on worldwide healthcare systems; immunosenescence and the coexistence of multiple comorbidities determine complex polypharmacy regimens with an increase in drug-drug interactions and spread of multidrug-resistance infections. Aging-induced pharmacokinetic and pharmacodynamic changes can additionally increase the risk of inappropriate drug dosing, with underexposure that is associated with antimicrobial resistance and overexposure that may lead to adverse effects and poor adherence because of low tolerability. These issues need to be considered when starting antimicrobial prescriptions. National and international efforts have been made towards the implementation of antimicrobial stewardship (AMS) interventions to help clinicians improve the appropriateness and safety of antimicrobial prescriptions in both acute and long-term care settings. AMS programs were shown to decrease consumption of antimicrobials and to improve safety in hospitalized patients and older nursing home residents. With the abundance of antimicrobial prescriptions and the recent emergence of multidrug resistant pathogens, an in-depth review of antimicrobial prescriptions in geriatric clinical practice is needed. This review will discuss the special considerations for older individuals needing antimicrobials, including risk factors that shape risk profiles in geriatric populations as well as an evidence-based description of antimicrobial-induced adverse events in this patient population. It will highlight agents of concern for this age group and discuss interventions to mitigate the effects of inappropriate antimicrobial prescribing.
Collapse
Affiliation(s)
- Luca Soraci
- Unit of Geriatric Medicine, IRCCS INRCA, 87100, Cosenza, Italy
| | - Antonio Cherubini
- Geriatria, Accettazione geriatrica e Centro di ricerca per l'invecchiamento, IRCCS INRCA, Ancona, Italy
| | - Luca Paoletti
- Geriatria, Accettazione geriatrica e Centro di ricerca per l'invecchiamento, IRCCS INRCA, Ancona, Italy
| | | | - Filippo Luciani
- Infectious Diseases Unit of Annunziata Hospital, Cosenza, Italy
| | - Pasqualina Laganà
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | | | | | | | | |
Collapse
|